Allergies Antibody Immune Response In-Vivo 
The Pharma Data
JULY 8, 2021
“We are proud to advance an innovative, first-in-class monoclonal antibody that targets the top of the inflammatory cascade and represents a potentially transformative treatment option for a broad population of patients with severe asthma. .” Amgen (NASDAQ:AMGN) announced that the U.S. Reese, M.D., About Severe Asthma.
The Pharma Data
APRIL 27, 2021
Progress on implementation of the Corporate Social Responsibility strategy. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% at CER driven by growth drivers Dupixent ® and Vaccines. Specialty Care sales grew 15.3%, due to strong Dupixent ® performance (+45.6% to €1,047 million) and oncology launches.
Expert insights. Personalized for you.
52 
Let's personalize your content